Immunohistochemical antibodies in breast cancer HER2 diagnostics

A comparative immunohistochemical and fluorescence in situ hybridization study

Kristof Egervari, Zoltan Szollosi, Z. Nemes

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Overexpression and/or gene amplification of the HER2 oncogene predicts worse prognosis and altered sensitivity to chemotherapy. Trastuzumab is capable of improving prognosis of HER2-positive breast cancer, but for the success of treatment appropriate HER2 testing is essential. Our aim was to determine the value of immunohistochemical (IHC) screening prior to fluorescence in situ hybridization (FISH). We assessed five conventional IHC assays (NCL-CB11, Pathway CB11, CBE356, CBE1, HercepTest) and the novel rabbit monoclonal antibody, RM-4B5, combined with FISH on 199 invasive breast cancer cases. Taking FISH as the endpoint, we calculated sensitivity, specificity, positive and negative predictive values (PPV, NPV) and accuracy for all IHC assays with either taking both 2+/3+ cases or only 3+ cases as IHC positives. With 2+/3+ cases HercepTest showed 100% sensitivity and NPV, while the highest specificity, PPV and accuracy was associated with RM-4B5 (97.36, 80 and 95.34%, respectively). The second highest values belonged to either NCL-CB11 or Pathway CB11. When calculating only with 3+ cases, the results were reversed with increased specificity, PPV and accuracy. Our findings suggest that improving sensitivity by using two parallel IHC reactions might be beneficial; we recommend primarily HercepTest and Pathway CB11. Nevertheless, we may consider performing FISH analysis without prior IHC screening.

Original languageEnglish
Pages (from-to)18-27
Number of pages10
JournalTumor Biology
Volume29
Issue number1
DOIs
Publication statusPublished - May 2008

Fingerprint

Fluorescence In Situ Hybridization
Breast Neoplasms
Antibodies
Gene Amplification
Oncogenes
Monoclonal Antibodies
Rabbits
Drug Therapy
Sensitivity and Specificity
Therapeutics

Keywords

  • Breast cancer
  • Fluorescence in situ hybridization
  • HER2
  • Immunohistochemistry
  • Tissue microarray

ASJC Scopus subject areas

  • Cancer Research

Cite this

Immunohistochemical antibodies in breast cancer HER2 diagnostics : A comparative immunohistochemical and fluorescence in situ hybridization study. / Egervari, Kristof; Szollosi, Zoltan; Nemes, Z.

In: Tumor Biology, Vol. 29, No. 1, 05.2008, p. 18-27.

Research output: Contribution to journalArticle

@article{b191da227e98454c8db1b8d6b42b8b1f,
title = "Immunohistochemical antibodies in breast cancer HER2 diagnostics: A comparative immunohistochemical and fluorescence in situ hybridization study",
abstract = "Overexpression and/or gene amplification of the HER2 oncogene predicts worse prognosis and altered sensitivity to chemotherapy. Trastuzumab is capable of improving prognosis of HER2-positive breast cancer, but for the success of treatment appropriate HER2 testing is essential. Our aim was to determine the value of immunohistochemical (IHC) screening prior to fluorescence in situ hybridization (FISH). We assessed five conventional IHC assays (NCL-CB11, Pathway CB11, CBE356, CBE1, HercepTest) and the novel rabbit monoclonal antibody, RM-4B5, combined with FISH on 199 invasive breast cancer cases. Taking FISH as the endpoint, we calculated sensitivity, specificity, positive and negative predictive values (PPV, NPV) and accuracy for all IHC assays with either taking both 2+/3+ cases or only 3+ cases as IHC positives. With 2+/3+ cases HercepTest showed 100{\%} sensitivity and NPV, while the highest specificity, PPV and accuracy was associated with RM-4B5 (97.36, 80 and 95.34{\%}, respectively). The second highest values belonged to either NCL-CB11 or Pathway CB11. When calculating only with 3+ cases, the results were reversed with increased specificity, PPV and accuracy. Our findings suggest that improving sensitivity by using two parallel IHC reactions might be beneficial; we recommend primarily HercepTest and Pathway CB11. Nevertheless, we may consider performing FISH analysis without prior IHC screening.",
keywords = "Breast cancer, Fluorescence in situ hybridization, HER2, Immunohistochemistry, Tissue microarray",
author = "Kristof Egervari and Zoltan Szollosi and Z. Nemes",
year = "2008",
month = "5",
doi = "10.1159/000132567",
language = "English",
volume = "29",
pages = "18--27",
journal = "Tumor Biology",
issn = "1010-4283",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Immunohistochemical antibodies in breast cancer HER2 diagnostics

T2 - A comparative immunohistochemical and fluorescence in situ hybridization study

AU - Egervari, Kristof

AU - Szollosi, Zoltan

AU - Nemes, Z.

PY - 2008/5

Y1 - 2008/5

N2 - Overexpression and/or gene amplification of the HER2 oncogene predicts worse prognosis and altered sensitivity to chemotherapy. Trastuzumab is capable of improving prognosis of HER2-positive breast cancer, but for the success of treatment appropriate HER2 testing is essential. Our aim was to determine the value of immunohistochemical (IHC) screening prior to fluorescence in situ hybridization (FISH). We assessed five conventional IHC assays (NCL-CB11, Pathway CB11, CBE356, CBE1, HercepTest) and the novel rabbit monoclonal antibody, RM-4B5, combined with FISH on 199 invasive breast cancer cases. Taking FISH as the endpoint, we calculated sensitivity, specificity, positive and negative predictive values (PPV, NPV) and accuracy for all IHC assays with either taking both 2+/3+ cases or only 3+ cases as IHC positives. With 2+/3+ cases HercepTest showed 100% sensitivity and NPV, while the highest specificity, PPV and accuracy was associated with RM-4B5 (97.36, 80 and 95.34%, respectively). The second highest values belonged to either NCL-CB11 or Pathway CB11. When calculating only with 3+ cases, the results were reversed with increased specificity, PPV and accuracy. Our findings suggest that improving sensitivity by using two parallel IHC reactions might be beneficial; we recommend primarily HercepTest and Pathway CB11. Nevertheless, we may consider performing FISH analysis without prior IHC screening.

AB - Overexpression and/or gene amplification of the HER2 oncogene predicts worse prognosis and altered sensitivity to chemotherapy. Trastuzumab is capable of improving prognosis of HER2-positive breast cancer, but for the success of treatment appropriate HER2 testing is essential. Our aim was to determine the value of immunohistochemical (IHC) screening prior to fluorescence in situ hybridization (FISH). We assessed five conventional IHC assays (NCL-CB11, Pathway CB11, CBE356, CBE1, HercepTest) and the novel rabbit monoclonal antibody, RM-4B5, combined with FISH on 199 invasive breast cancer cases. Taking FISH as the endpoint, we calculated sensitivity, specificity, positive and negative predictive values (PPV, NPV) and accuracy for all IHC assays with either taking both 2+/3+ cases or only 3+ cases as IHC positives. With 2+/3+ cases HercepTest showed 100% sensitivity and NPV, while the highest specificity, PPV and accuracy was associated with RM-4B5 (97.36, 80 and 95.34%, respectively). The second highest values belonged to either NCL-CB11 or Pathway CB11. When calculating only with 3+ cases, the results were reversed with increased specificity, PPV and accuracy. Our findings suggest that improving sensitivity by using two parallel IHC reactions might be beneficial; we recommend primarily HercepTest and Pathway CB11. Nevertheless, we may consider performing FISH analysis without prior IHC screening.

KW - Breast cancer

KW - Fluorescence in situ hybridization

KW - HER2

KW - Immunohistochemistry

KW - Tissue microarray

UR - http://www.scopus.com/inward/record.url?scp=44349099693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44349099693&partnerID=8YFLogxK

U2 - 10.1159/000132567

DO - 10.1159/000132567

M3 - Article

VL - 29

SP - 18

EP - 27

JO - Tumor Biology

JF - Tumor Biology

SN - 1010-4283

IS - 1

ER -